ライフサイエンスコーパス: treatment

1 al and complete responders one day after the treatment.

2 ity and 98.8% were deemed unrelated to study treatment.

3 as an excellent candidate for periodontitis treatment.

4 Ai or sham (injection plus standard of care) treatment.

5 the highest risk that may require supportive treatment.

6 tion, and its role in cancer progression and treatment.

7 l states throughout melanoma progression and treatment.

8 , thereby promoting cell survival after drug treatment.

9 ects were partially restored by pregnenolone treatment.

10 ned in OUD treatment after completion of DAA treatment.

11 e varicosities resolved in mice with delayed treatment.

12 a profile did not change because of the film-treatment.

13 ptimize personalized immunotherapy in cancer treatment.

14 ndomized, and 199 received >=1 dose of study treatment.

15 t demographics, IDH/MGMT mutation status, or treatment.

16 es, and serious adverse events (SAEs) during treatment.

17 CEBPB, miR-520G overexpression or IFN-gamma treatment.

18 dentified TB status at distinct times during treatment.

19 s no apparent interaction between Px and Iso treatment.

20 tients who had poorer outcomes following RAI treatment.

21 of artifacts following intracranial aneurysm treatment.

22 anosheets before and after superheated steam treatment.

23 and lethal neurodegenerative disease with no treatment.

24 s faced by individuals receiving sex steroid treatment.

25 as done in all patients randomly assigned to treatment.

26 d them from controls and increased following treatment.

27 of disease or tumor recurrence after initial treatment.

28 acterial strains further complicates patient treatment.

29 an advanced oxidation process (AOP) in water treatment.

30 insight into the multifaceted effects of HU treatment.

31 clinicians from providing appropriate sepsis treatment.

32 l levels can be applicable during wastewater treatment.

33 important biomarker for cancer diagnosis and treatment.

34 op could potentially be exploited for cancer treatment.

35 velopment of more efficacious antidepressant treatments.

36 c pontine gliomas (DIPGs) are fatal and lack treatments.

37 nderlying UC has led to the emergence of new treatments.

38 treatment, and 1 (0.2%) of 517 who completed treatment (1951, 290, and 31 cases/100 000 person-years,

39 713], P < 0.001), and for those on EFV-based treatment (60% [12/20] vs 86% [214/248], P = 0.002) and

40 /248], P = 0.002) and for those on DTG-based treatment (61/92 [66%] vs 84% [391/465] P < 0.001, P for

41 Archived plasma obtained pre- and post-TCZ treatment (8 mg/kg, 6x, monthly) from 12 cAMR patients w

42 ped in 49 (9.8%) of 446 who did not initiate treatment, 8 (1.8%) of 443 who received partial treatmen

43 n the soil microbiome due to antecedent soil treatment additionally influence denitrification.

44 Yield increases resulted from the basalt treatment after 120 days without P- and K-fertilizer add

45 atment during therapy, and 9 remained in OUD treatment after completion of DAA treatment.

46 Treatment after disease onset potently blocks progressio

47 dy compared the performance of exchange plus treatment against treatment alone by modeling establishm

48 Investigators and participants were aware of treatment allocation.

49 rformance of exchange plus treatment against treatment alone by modeling establishment rates of nonin

50 In on-treatment analysis, suppression below 1,000 copies/mL wa

51 Toxicity between treatment and 3 mo was evaluated according to the Common

52 al suppression is recommended at 6 months of treatment and annually thereafter.

53 reatment assignment and interactions between treatment and baseline covariates.

54 o sensitize PC cells to arginine deprivation treatment and chemotherapy through targeting ASS1- and G

55 time, PSA velocity, and time between initial treatment and PET imaging was evaluated.

56 ession noise is important for improving drug treatment and the performance of synthetic biological sy

57 rmogenesis responded inconsistently to FGF21 treatment and weight loss.

58 atment, 8 (1.8%) of 443 who received partial treatment, and 1 (0.2%) of 517 who completed treatment (

59 is information can be used to guide testing, treatment, and public health prevention efforts.

60 opmental models, genetic perturbations, drug treatments, and disease states.

61 s study aims to investigate whether the heat treatment applied during the production of black onion,

62 ug Conjugates (ADCs) developed as a targeted treatment approach to deliver toxins directly to cancer

63 Patients that undergo a TACE-treatment are categorised in partial and complete respon

64 Few effective treatments are available for patients with metastatic MC

65 The available treatments are hampered by issues such as toxicity, vari

66 cance, in rates of RNFLT change in the UKGTS treatment arms was enhanced and RNFLT change became a st

67 age, the difference in decline between the 2 treatment arms was not significant (P = .09).

68 oped on RCT data by incorporating a term for treatment assignment and interactions between treatment

69 ower serum creatinine and KCCQ-OS scores and treatment assignment to MitraClip.

70 impact on cochlear clock rhythms only after treatment at nighttime suggesting that cisplatin can mod

71 ted to investigate the effects of irrigation treatments at different physiological growth stages (bef

72 Among various treatments available for DMD, antisense oligonucleotides

73 medicine in cancer is matching patients and treatments based on the genomic characteristics of an in

74 17/group) after seven-day oral metronidazole treatment: behavioral counseling only (control), or coun

75 maintains efficacy and safety while reducing treatment burden associated with regular IVT injections

76 are resistant to conventional anticonvulsant treatment but are well-controlled by pyridoxine (PN).

77 ith an ARNI and baseline eGFR, but suggested treatment-by-subgroup interactions for subgroups based o

78 Using an optimal DPA concentration, the treatment can simultaneously remove both long-chain insu

79 At >=6 months after conservative treatment, case fatality was 30% (95% CI 25% to 30%) and

80 Nondenaturing sodium bisulfite treatment catalyzes the conversion of unpaired cytosines

81 ry, benefits that persisted for months after treatment cessation.

82 disequilibrium compounds persist long after treatment changes have been made.

83 ings are supported by clinical data from ICB treatment cohorts.

84 amination at the end of the first year after treatment completion combined with 12 months of secondar

85 During the nivolumab treatment cycle, his pertinent laboratory values and phy

86 e of biomarkers to guide prognostication and treatment decision-making.

87 maintained despite the survivorship in both treatments declining in continued exposure to OA.

88 As such, while all treatments depleted a significant proportion of Tregs, t

89 On-demand AZD9412 treatment did not numerically reduce the number of exace

90 , 0.19; 95% CI, 0.05 to 0.75), whereas later treatment did not.

91 an urgent unmet need to develop mechanistic treatments directed at root causes of AF.

92 o completed at least one full-scheduled post-treatment disease assessment.

93 ines we examined in vitro cisplatin/JH-RE-06 treatment does not increase apoptosis.

94 (46.4%) engaged in opioid use disorder (OUD) treatment during therapy, and 9 remained in OUD treatmen

95 as from temporal trends, (2) inefficiency in treatment effect estimation, (3) volatility in sample-si

96 ation of treatment effect, after the maximum treatment effect was observed.

97 nt represented the point of stabilization of treatment effect, after the maximum treatment effect was

98 Moreover, almost all trials have quantified treatment effects by using the hazard ratio, which is di

99 effect sizes of interest, revealed that the treatment effects observed in four out of five of our ex

100 The pooled treatment effects showed consistent benefits for subgrou

101 , Neural Networks, Neuro-Oncology, Oncology, Treatment Effects, Tumor Response Supplemental material

102 Treatment efficacy for diabetes mellitus is largely dete

103 in the ixekizumab Q2W group had at least one treatment-emergent adverse event.

104 at least one dose of study drug in terms of treatment-emergent adverse events.

105 in 16% and 31% (no drug-related deaths), and treatment-emergent nephrotoxicity in 10% and 56% (P = .0

106 inking days during the subsequent 2 weeks of treatment engagement.

107 in carbon stability and tree survival across treatments, expecting that both carbon stability and sur

108 Main outcomes were treatment failure (the proportion of women in which surg

109 The basis of fluoroquinolone treatment failure for Mycoplasma genitalium is poorly un

110 Treatment failure was defined as (1) any further surgica

111 5 mg twice daily plus corticosteroids, until treatment failure, unacceptable toxicity, or death.

112 al pocket) mainly contributed to determine a treatment failure.

113 ology developed involves two sequential acid treatments followed by stepwise ethanol precipitation.

114 esting may inform prevention, diagnosis, and treatment for a broad range of CF carrier-related condit

115 f age who had received stable lipid-lowering treatment for at least 4 weeks before screening and who

116 at has shown potential in animal models as a treatment for eosinophilic gastritis and duodenitis.

117 ucoma, but only 2.6% had used marijuana as a treatment for glaucoma.

118 Combined treatment for SAM and MAM is non-inferior to standard ca

119 The mainstay of early treatment for SCI for all cases was blood pressure contr

120 dequately controlled despite optimal medical treatment for type 2 diabetes.

121 tigating the safety and efficacy of systemic treatments for AD up to February 2020.

122 Many treatments for irritable bowel syndrome are available to

123 targeting stressors and stress allostasis in treatments for SUDs.

124 (11)C-choline PET/CT positivity and initial treatment, Gleason score, National Comprehensive Cancer

125 onse at week 24 in all patients per assigned treatment group.

126 The treatment groups were surgery alone, radiotherapy (55.8

127 oss did not differ significantly between the treatment groups, and both techniques induced a minimal

128 d or moderate in severity and similar across treatment groups.

129 al landmarks and OSAS could help to stratify treatments, guiding choice towards those which most effe

130 ative allergens, allergy immunotherapy (AIT) treatment habits differ significantly across different g

131 ultiple previous standard-of-care preventive treatments had failed.

132 Patients who received pretransplant dialysis treatment in a state with a high rate of dialysis mortal

133 the same duration of pretransplant dialysis treatment in a state with a lower mortality rate.

134 IL6 is targeted as part of treatment in adoptive cell therapy (ACT) because of its

135 at the proportion of participants commencing treatment in the primary care arm (75%, 43/57) was signi

136 se and expand the clinical benefits of these treatments in patients with diverse cancers.

137 A doubling time (2.3 mo) and extensive prior treatment, including prior docetaxel (84%), cabazitaxel

138 In vitro studies showed that rhIGF-1/BP3 treatment increased lung endothelial cell and alveolar t

139 losis (TB) given standard first-line anti-TB treatment indicated an increased risk of multidrug-resis

140 Fulvestrant treatment induced a similar early metabolic response for

141 Likewise, BMP9/10 treatment induced an ALK1-dependent phenotypic switch fr

142 Treatment induced recovery of respiratory activity norma

143 Butyrate treatment inhibited allergen-induced histamine release a

144 SMI#9 treatment inhibited melanoma cell proliferation but not

145 l probability would increase with increasing treatment intensity (decreasing basal area).

146 A one-time LTBI testing and treatment intervention among non-U.S.-born residents was

147 For all patients with Parkinson disease, treatment is symptomatic, focused on improvement in moto

148 ultimorbidity when the benefits of continued treatment may not outweigh the harms.

149 Recent advances in new cancer treatment modalities (e.g., gene and immune therapies) a

150 PC) gene therapy has emerged as an effective treatment modality for monogenic disorders of the blood

151 cation of these EFs is as an emerging cancer treatment modality.

152 The high rates of 2 or 3 treatment modifications over the 4-year period suggest a

153 Randomized trials of BP pharmacologic treatment (more intensive BP goal or active agent) that

154 a manageable safety profile in patients with treatment-naive, or relapse or refractory Waldenstrom ma

155 ese findings suggest that in addition to TMZ treatment, NF-kappaB can be used as a potential target t

156 These effects were diminished upon the same treatment of A549 cells transfected with either p53 siRN

157 Patients undergoing treatment of acute lymphoblastic leukemia (ALL) are at r

158 Anthracyclines used in the treatment of acute myelogenous leukemia (AML) inhibit th

159 potential of these combined therapies in the treatment of advanced atherosclerosis.

160 with best supportive care in the second-line treatment of advanced hepatocellular carcinoma over a li

161 istically novel therapeutic approach for the treatment of affective and stress-related neuropsychiatr

162 may be a viable therapeutic approach in the treatment of age-related dry eye disease.

163 Delayed diagnosis and treatment of AKI due to the lack of efficient early diag

164 erapeutic anti-IgE antibody approved for the treatment of allergic conditions.

165 ylase inhibitors (HIs) are effective for the treatment of anemia in chronic kidney disease patients a

166 s ICT12035, can provide a new avenue for the treatment of cancers.

167 tion is the side effects associated with the treatment of chemotherapy or radiotherapy.

168 ugmentation cultures coinjection for in situ treatment of chlorinated ethenes and ClO(4)(-).

169 d trials plan to evaluate ACEIs and ARBs for treatment of COVID-19.

170 coupled receptors (GPCRs) are targets in the treatment of dementia, and the arrestins are common to t

171 KI-7 represents a promising strategy for the treatment of diabetic vascular complications.

172 patients and may also be beneficial for the treatment of diseases such as chronic inflammation and i

173 ate that residual endotoxin after successful treatment of donor bacterial pneumonia promotes PGD thro

174 valuated in a phase 2 clinical study for the treatment of Duchenne muscular dystrophy (DMD).

175 However, treatment of flies and primary Schwann cells with an ant

176 enhancement purely relying on post-printing treatment of hydrogel constructs.

177 Notably, treatment of infected wild-type mice with apoptotic cell

178 odrug design for the most effective and safe treatment of inflammatory arthritis.

179 dicating their therapeutic potential for the treatment of inflammatory diseases.

180 ior to intravenous antibiotics for the early treatment of KLA.

181 her investigation of IL-1beta inhibition for treatment of large joint osteoarthritis.

182 sm and development of new strategies for the treatment of lethal PC.

183 ation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa).

184 LVB have become increasingly popular in the treatment of lymphedema.

185 DAC) have lagged behind advances made in the treatment of many other malignancies over the past few d

186 In vitro, IL6 treatment of MDSC-like cells activated STAT3, increased

187 ab was superior to placebo in the preventive treatment of migraine and was safe and well tolerated in

188 as the potential for use as a target for the treatment of NAFLD.

189 In the absence of controlled trials, treatment of neonatal seizures has changed minimally des

190 to control A. fumigatus, is complicating the treatment of patients.

191 novel behavioral and brain-based targets for treatment of pediatric anxiety disorders.

192 ic review of published data on antimicrobial treatment of plague reported in aggregate.

193 ion and nuclear accrual notably increased by treatment of SH-SY5Y cells with PMA and it correlated wi

194 interventions that might result in efficient treatment of social-emotional disorders.

195 finding warrants the modeling of concurrent treatment of TB and HIV to potentially reduce the risk o

196 R) and p53-null mice was suppressed upon the treatment of the mTOR inhibitor.

197 A limitation for the treatment of unresectable cholangiocarcinoma (CCA) is it

198 and provides newer options for diagnosis and treatment of valvular heart disease.

199 (HCT116 and CAL27) to single and combination treatments of radiation (0-20 Gy), and hyperthermia at 4

200 actor and anti-interleukin-12/interleukin-23 treatment on SB and colonic ACE2 expression in 3 clinica

201 assess the effects of long-term doxycycline treatment on the aortic ultrastructure and skin dermis o

202 posure SUDV therapy and provides a potential treatment option for managing human SUDV infection.

203 Deep brain stimulation (DBS) is an effective treatment option for patients with refractory obsessive-

204 at fecal microbiota transplantation may be a treatment option in sepsis associated with immunosuppres

205 Currently, no treatment options are available to establish remyelinati

206 The number of molecularly stratified treatment options available to patients with colorectal

207 ore research is needed to establish the best treatment options for these high-risk patients.

208 periodontal disease pathogenesis may lead to treatment options that address individual biological var

209 Given the current lack of third-line treatment options, this approach warrants consideration

210 ost relevant previous classifications into a treatment-oriented diagnostic matrix.

211 Our aim in this review was to investigate treatment outcomes among PWID and patients on OST in com

212 The study documents the end-of-treatment outcomes, culture-conversion rates, and seriou

213 as underscored the weaknesses in our current treatment paradigm for UTIs.

214 still relies on an energy-intensive thermal treatment pathway (Acheson process) at about 3000 degree

215 tralstat in patients with HAE over a 24-week treatment period (the phase 3 APeX-2 trial).

216 0-fold lower than baseline during the 3 year-treatment period and 10-fold lower during the follow-up

217 Findings were consistent during the on-treatment period and in those with incidental VTE.

218 ey influence heavy drinking during the early treatment phase.

219 rs and reducing nutrient loads to wastewater treatment plants.

220 iferation.Conclusions: Postnatal rhIGF-1/BP3 treatment preserved lung structure and prevented RVH in

221 of complication-free tumour under different treatment protocols.

222 ignature associated with response to GS-9688 treatment provides insights into the immune mechanisms t

223 Comparative data are limited and describe re-treatment rates rather than retinal structural outcomes

224 n is expected to better drive clinical care, treatment recommendations, and future research.

225 SaB patient responses and guide personalized treatment regimens could reduce mortality.

226 All treatment-related adverse events were mild or moderate i

227 Thirteen percent of patients (n = 5) had treatment-related grade 3 or 4 adverse events.

228 release syndrome (CRS) is a life-threatening treatment-related toxicity that limits the full therapeu

229 ing electroanalytical properties, absence of treatment requirement, cost-effectiveness (c.a. 1 euro /

230 fferentiated invasive states associated with treatment resistance and defects in antigen presentation

231 ses driving the eco-evolutionary dynamics of treatment-resistant cancer populations.

232 by the U.S. Food and Drug Administration for treatment-resistant depression.

233 designated as having 'difficult to treat', 'treatment-resistant' or 'refractory' RA.

234 inically relevant tumour behaviours, such as treatment response and emergence of drug resistance: inf

235 h fluorine 18 fluorodeoxyglucose PET/MRI for treatment response assessment in children and young adul

236 ion of noninvasive biomarkers for monitoring treatment response, tests for quantifying the "net state

237 e used as a potential target to increase the treatment's outcomes.

238 interleukin 18 levels declined by the end of treatment, sCD14 levels did not change, and sCD163, MCP-

239 local minimum of the first derivative after treatment start; this point represented the point of sta

240 privation and the information for developing treatment strategies for disc degeneration.

241 k of reactivation of TB due to HIV to inform treatment strategies in patients with M. tuberculosis/HI

242 and could inform the design of personalized treatment strategies that can be tested in future studie

243 toring technologies, and the optimization of treatment strategies, ranging from stroke prophylaxis to

244 well as on its presentation and appropriate treatment strategies.

245 isms of virus-induced brain dysfunction, and treatment strategies.

246 facilitates efficient targeted therapies and treatment strategies.

247 ween 7 and 9 months appears to be reasonable treatment strategy for children without recurrent infect

248 ression of IL17RA is a promising new topical treatment strategy for psoriasis.

249 o or an outdated antiviral regimen, 48 other treatment studies, and 33 cohort studies, with a total o

250 tion was compared with that of the Amblyopia Treatment Study (ATS) and the authors' clinic protocol.

251 Survival analysis demonstrated treatment success in 70%, 45%, and 27% of eyes at 6, 12,

252 shed and incorporation of adjunctive upfront treatments such as chemotherapy and novel anti-androgen

253 orbidity as well as use of appropriate local treatments such as radiation therapy, orthopaedic surger

254 Strengthening of testing programs and treatment support, along with prevention interventions,

255 tained virological response at 12 weeks post-treatment (SVR12) was the primary outcome.

256 ls with AF may be unaware and do not receive treatment that could prevent a stroke.

257 on (iTBS) is a noninvasive brain stimulation treatment that has been approved by the U.S. Food and Dr

258 In the second growing season of treatment, the shrub warming response rate increased to

259 of atrial fibrillation that also hampers its treatment; the underlying molecular mechanisms are poorl

260 eperfusion by thrombolysis or interventional treatments; those patients are hemodynamically unstable

261 nt, requiring at least 6 months of multidrug treatment to achieve cure(1).

262 Seed priming uses treatments to improve seed germination and thus potentia

263 toxicities that are particularly relevant to treatment tolerability for patients living with indolent

264 Compared to single-agent sunitinib treatment, tumors in sunitinib-treated EpsilonC-betaKO m

265 By 2018, cumulative HCV treatment uptake in those ever eligible for treatment wa

266 ith recent systemic anticancer therapy to no treatment was 1.17 (95% CI, 0.83-1.64; N = 736).

267 treatment uptake in those ever eligible for treatment was 91% (336/371).

268 Furthermore, treatment was associated with a significant reduction in

269 Importantly, bumetanide treatment was associated with increased neuronal and net

270 thics committee, a long-term supplementation treatment was introduced.

271 Finally, we showed that interleukin-4 treatment was sufficient to increase the number of MGCs

272 Treatment was well tolerated in most however serious AEs

273 vs 34.7%; stabilized inverse probability of treatment weighting hazard ratio, 0.525; 95% CI, 0.240-1

274 vs 26.3%; stabilized inverse probability of treatment weighting hazard ratio, 0.539; 95% CI, 0.224-1

275 Brain changes in response to binge EtOH treatment were more pronounced in young relative to olde

276 and scheduled for endovascular embolization treatment were prospectively included.

277 lected on traps associated with all in-field treatments were identified to species to assess beetle d

278 Different rice treatments were involved i.e. three soaking times (0, 15

279 d with BCVA gain after 7 monthly ranibizumab treatments were younger age (P < 0.0001) and worse basel

280 Treatment with 20% beeswax was the most suitable for ind

281 Finite, short-duration treatment with a clinically relevant dose of GS-9688 is

282 Both depletion of Pyk2 and treatment with a Pyk2 kinase inhibitor increased viral D

283 Treatment with aminoglycosides such as streptomycin or g

284 s for subgroups based on age, sex, diabetes, treatment with an ARNI and baseline eGFR, but suggested

285 Treatment with anti-vascular endothelial growth factor a

286 The treatment with FDC of sofosbuvir and daclatasvir achieve

287 slows bacterial growth more effectively than treatment with free lysozyme.

288 These data suggest that long-term treatment with gemcitabine leads to extensive reprogramm

289 12 cAMR patients who failed standard of care treatment with intravenous immune globulin + rituximab w

290 Treatment with lovastatin, a mevalonate biosynthesis inh

291 Subsequent treatment with low-dose EPO triggered robust RBC product

292 We show that treatment with lysozyme-functionalized origami slows bac

293 t has been hypothesized that the benefits of treatment with renin-angiotensin system inhibitors in SA

294 Pre-treatment with SKF-83566, a D1 receptor antagonist, atte

295 Treatment with Tat-A and Tat-B caused membrane disruptio

296 ulcerative colitis (UC), in which first-time treatment with vedolizumab was initiated.

297 to suprachoroidally injected CLS-TA or sham treatment, with administrations at day 0 and week 12.

298 In a prespecified subgroup analysis, treatment within 7 days after symptom onset led to lower

299 Treatments without dispersal had lower soil microbial bi

300 d inferior IPA compared with tirofiban; both treatments yielded greater IPA compared with chewed pras